A naukri.com initiative
Bioengineer
2d
360
Image Credit: Bioengineer
Low-Dose Apixaban Proves Equivalent to Full Dose in Preventing VTE Recurrence in Cancer Patients
- The API-CAT trial presented at the American College of Cardiology's Annual Scientific Session offers insights into using low-dose apixaban for VTE management in cancer patients.
- Patients with active cancer are at high risk of VTE, the second leading cause of mortality among them, due to cancer-related factors and treatments.
- The API-CAT trial investigated reduced-dose apixaban versus full dose, showing similar efficacy in preventing VTE recurrence with lower bleeding risk.
- Data from the trial, involving 1,766 patients with diverse cancer types, revealed a lower VTE recurrence rate in the low-dose group.
- The reduced-dose group also experienced significantly lower rates of clinically relevant bleeding compared to the full-dose group.
- The study demonstrates the potential of low-dose apixaban as a safe and effective option for extended VTE management in cancer patients.
- Despite positive outcomes, considerations regarding optimal treatment duration and racial differences in efficacy remain as study limitations.
- Research implications include potential updates to clinical guidelines and ongoing investigations into refining anticoagulation strategies for cancer patients.
- Lowering the dose of apixaban may offer a safer approach without compromising overall survival in cancer patients with VTE.
- The API-CAT trial's findings contribute valuable insights to improving VTE management in cancer patients and may influence future treatment standards.
Read Full Article
21 Likes
For uninterrupted reading, download the app